Identification of a Novel Long Non-coding RNA, lnc-ATMIN-4:2, and its Clinicopathological and Prognostic Significance in Advanced Gastric Cancer

Cancer Genomics Proteomics. 2022 Nov-Dec;19(6):761-772. doi: 10.21873/cgp.20358.

Abstract

Background/aim: Long non-coding RNAs (lncRNAs) are emerging as significant regulators of gene expression and a novel promising biomarker for cancer diagnosis and prognosis. This study identified a novel, differentially expressed lncRNA in advanced gastric cancer (AGC), Inc-ATMIN-4:2, and evaluated its clinicopathological and prognostic significance.

Patients and methods: Whole transcriptome sequencing was performed to identify differentially expressed lncRNAs in AGC tissue samples. We also analyzed lnc-ATMIN-4:2 expression in 317 patients with AGC using RNA in situ hybridization.

Results: High (>30 dots) lnc-ATMIN-4:2 expression significantly correlated with younger age, poorly differentiated histology, diffuse type, deeper invasion depth, perineural invasion, lymph node metastasis, and higher stage group. In addition, high lnc-ATMIN-4:2 expression was significantly associated with worse overall survival in patients with AGC.

Conclusion: This study elucidated the significance of lncRNAs in AGC and indicated the value of lnc-ATMIN-4:2 expression as a predictive biomarker for the overall survival of patients with AGC.

Keywords: RNA in situ hybridization; Stomach cancer; advanced gastric cancer; lnc-ATMIN-4:2; long non-coding RNA; prognosis; whole transcriptome sequencing.

MeSH terms

  • Humans
  • Lymphatic Metastasis
  • Prognosis
  • RNA, Long Noncoding* / genetics
  • Stomach Neoplasms* / pathology
  • Transcription Factors

Substances

  • RNA, Long Noncoding
  • ATMIN protein, human
  • Transcription Factors